Faiyaz Ahmad

List of Publications by Year
in descending order

44 papers	4,714 citations	159585 30 h-index	265206 42 g-index
44 all docs	44 docs citations	44 times ranked	6789 citing authors

#	Article	IF	Citations
1	Potent PDE4 inhibitor activates AMPK and Sirt1 to induce mitochondrial biogenesis. PLoS ONE, 2021, 16, e0253269.	2.5	3
2	Phosphodiesterase type 3A (PDE3A), but not type 3B (PDE3B), contributes to the adverse cardiac remodeling induced by pressure overload. Journal of Molecular and Cellular Cardiology, 2019, 132, 60-70.	1.9	14
3	Functions of PDE3 Isoforms in Cardiac Muscle. Journal of Cardiovascular Development and Disease, 2018, 5, 10.	1.6	26
4	White to beige conversion in PDE3B KO adipose tissue through activation of AMPK signaling and mitochondrial function. Scientific Reports, 2017, 7, 40445.	3.3	24
5	Specific Sirt1 Activator-mediated Improvement in Glucose Homeostasis Requires Sirt1-Independent Activation of AMPK. EBioMedicine, 2017, 18, 128-138.	6.1	30
6	Effects of heterologous expression of human cyclic nucleotide phosphodiesterase 3A (hPDE3A) on redox regulation in yeast. Biochemical Journal, 2016, 473, 4205-4225.	3.7	1
7	Phosphodiesterase 3B (PDE3B) regulates NLRP3 inflammasome in adipose tissue. Scientific Reports, 2016, 6, 28056.	3.3	34
8	The Role of PDE3B Phosphorylation in the Inhibition of Lipolysis by Insulin. Molecular and Cellular Biology, 2015, 35, 2752-2760.	2.3	73
9	Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2253-62.	7.1	65
10	Regulation of Sarcoplasmic Reticulum Ca2+ ATPase 2 (SERCA2) Activity by Phosphodiesterase 3A (PDE3A) in Human Myocardium. Journal of Biological Chemistry, 2015, 290, 6763-6776.	3.4	73
11	Advances in targeting cyclic nucleotide phosphodiesterases. Nature Reviews Drug Discovery, 2014, 13, 290-314.	46.4	614
12	Clinical and Molecular Genetics of the Phosphodiesterases (PDEs). Endocrine Reviews, 2014, 35, 195-233.	20.1	228
13	Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19778-19783.	7.1	23
14	A Role for Phosphodiesterase 3B in Acquisition of Brown Fat Characteristics by White Adipose Tissue in Male Mice. Endocrinology, 2013, 154, 3152-3167.	2.8	21
15	Phosphodiesterase Type 3A Regulates Basal Myocardial Contractility Through Interacting With Sarcoplasmic Reticulum Calcium ATPase Type 2a Signaling Complexes in Mouse Heart. Circulation Research, 2013, 112, 289-297.	4.5	114
16	Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases. Cell, 2012, 148, 421-433.	28.9	1,162
17	From PDE3B to the regulation of energy homeostasis. Current Opinion in Pharmacology, 2011, 11, 676-682.	3.5	111
18	Phosphodiesterase 4D Regulates Baseline Sarcoplasmic Reticulum Ca ²⁺ Release and Cardiac Contractility, Independently of L-Type Ca ²⁺ Current. Circulation Research, 2011, 109, 1024-1030.	4.5	84

#	Article	IF	Citations
19	Interaction of phosphodiesterase 3A with brefeldin A-inhibited guanine nucleotide-exchange proteins BIG1 and BIG2 and effect on ARF1 activity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6158-6163.	7.1	23
20	Differential regulation of adipocyte PDE3B in distinct membrane compartments by insulin and the Î²3-adrenergic receptor agonist CL316243: effects of caveolin-1 knockdown on formation/maintenance of macromolecular signalling complexes. Biochemical Journal, 2009, 424, 399-410.	3.7	40
21	Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB. Biochemical Journal, 2007, 404, 257-268.	3.7	49
22	Multisite phosphorylation of adipocyte and hepatocyte phosphodiesterase 3B. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 584-592.	4.1	26
23	Plasma membrane cyclic nucleotide phosphodiesterase 3B (PDE3B) is associated with caveolae in primary adipocytes. Cellular Signalling, 2006, 18, 1713-1721.	3.6	43
24	Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3Bâ€“null mice. Journal of Clinical Investigation, 2006, 116, 3240-3251.	8.2	156
25	Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3 and Their Contribution to cAMP Hydrolytic Activity in Subcellular Fractions of Human Myocardium. Journal of Biological Chemistry, 2005, 280, 39168-39174.	3.4	99
26	Effects of the Human Immunodeficiency Virus-Protease Inhibitor, Ritonavir, on Basal and Catecholamine-Stimulated Lipolysis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3251-3261.	3.6	19
27	Adenovirus-Mediated Overexpression of Murine Cyclic Nucleotide Phosphodiesterase 3B. , 2005, 307, 093-108.		1
28	Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3A in Cardiac Myocytes. Journal of Biological Chemistry, 2002, 277, 38072-38078.	3.4	109
29	Tumor Necrosis Factor-Â Stimulates Lipolysis in Differentiated Human Adipocytes Through Activation of Extracellular Signal-Related Kinase and Elevation of Intracellular cAMP. Diabetes, 2002, 51, 2929-2935.	0.6	372
30	Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochemical Journal, 2001, 353, 41-50.	3.7	45
31	Cyclic Nucleotide Phosphodiesterase 3B Is a Downstream Target of Protein Kinase B and May Be Involved in Regulation of Effects of Protein Kinase B on Thymidine Incorporation in FDCP2 Cells. Journal of Immunology, 2000, 164, 4678-4688.	0.8	58
32	Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases. Molecular and Cellular Biochemistry, 1998, 182, 91-99.	3.1	159
33	Regulation of Insulin Action by Protein Tyrosine Phosphatases. Vitamins and Hormones, 1998, 54, 67-96.	1.7	31
34	Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases. , 1998, , 91-99.		49
35	Functional Association between the Insulin Receptor and the Transmembrane Protein-tyrosine Phosphatase LAR in Intact Cells. Journal of Biological Chemistry, 1997, 272, 448-457.	3.4	91
36	Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. Metabolism: Clinical and Experimental, 1997, 46, 1140-1145.	3.4	121

#	Article	IF	Citations
37	Effect of tumor necrosis factor-Î± on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases. Journal of Cellular Biochemistry, 1997, 64, 117-127.	2.6	42
38	Purification, identification and subcellular distribution of three predominant protein-tyrosine phosphatase enzymes in skeletal muscle tissue. BBA - Proteins and Proteomics, 1995, 1248, 57-69.	2.1	44
39	Osmotic Loading of Neutralizing Antibodies Demonstrates a Role for Protein-tyrosine Phosphatase 1B in Negative Regulation of the Insulin Action Pathway. Journal of Biological Chemistry, 1995, 270, 20503-20508.	3.4	211
40	Increased abundance of specific skeletal muscle protein-tyrosine phosphatases in a genetic model of insulin-resistant obesity and diabetes mellitus. Metabolism: Clinical and Experimental, 1995, 44, 1175-1184.	3.4	116
41	Hypoglycemie activity of Pterocarpus marsupium wood. Journal of Ethnopharmacology, 1991, 35, 71-75.	4.1	35
42	Effect of age on the binding of lectin125I-PHA-B to pancreatic islets of ratin vitro and stimulation of some cellular events. Acta Diabetologica Latina, 1989, 26, 171-180.	0.2	2
43	Effect of some novel synthetic analogues of CCK-4 on insulin and glucagon secretion. Acta Diabetologica Latina, 1989, 26, 203-209.	0.2	3
44	Insulin like activity in (âˆ') epicatechin. Acta Diabetologica Latina, 1989, 26, 291-300.	0.2	70